Novo Nordisk (NVO) said Tuesday it has filed for European Medicines Agency approval of a new, higher dose of its obesity treatment Wegovy, or semaglutide.
The application is supported by clinical trial data showing that treatment with the higher 7.2 mg subcutaneous dose led to an average 21% reduction in body weight among people with obesity with or without type 2 diabetes, with one in three patients achieving 25% or more weight loss, Novo Nordisk said.
The higher dose had a safety profile consistent with the currently approved 2.4 mg dose, the company added.
Price: 69.36, Change: +0.04, Percent Change: +0.06
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。